Sensitivity of White Blood Cell DNA to Damage from UV Light Distinguishes Cancer Patients from Healthy Individuals
|
By LabMedica International staff writers Posted on 13 Aug 2014 |

Image: The single cell gel electrophoresis assay or “comet” test (Photo courtesy of the Belgian BioElectroMagnetics Group).
A simple test that measures the extent of damage to white blood cell DNA caused by exposure to ultraviolet light has the potential to detect individuals with cancer before the appearance of any detectable symptoms.
Investigators at the University of Bradford (United Kingdom) recently described the Lymphocyte Genome Sensitivity (LGS) test that they had developed. This test, which is based on "comet assay" technology, evaluates the damage caused to white blood cell DNA by exposure to different intensities of ultraviolet light (UVA).
The comet assay (single-cell gel electrophoresis) is a simple method for measuring DNA strand breaks in eukaryotic cells. Cells embedded in agarose on a microscope slide are dissolved with detergent and a high salt concentration to form nucleoids containing supercoiled loops of DNA linked to the nuclear matrix. Electrophoresis under alkaline conditions results in structures resembling comets, observed by fluorescence microscopy, with the intensity of the comet tail relative to the head reflecting the number of DNA breaks. Determine of the extent of DNA damage is obtained from visual analysis after DNA staining and calculation of fluorescence, which can be performed by manual scoring or automatically by imaging software.
For their study, the investigators looked at lymphocyte responses from 208 individuals: 20 with melanoma, 34 with colon cancer, four with lung cancer, 18 with suspected melanoma, 28 with polyposis, 10 with COPD (chronic obstructive pulmonary disease), and 94 healthy volunteers. Random and anonymous white blood cell samples were exposed to UVA light through five different depths of agar and then analyzed by the comet assay.
Results revealed that damage to DNA in white blood cells from cancer patients reached a stable plateau after treatment with different UVA intensities. In contrast the response of white blood cells from healthy individuals returned to control values.
Dr. Diana Anderson, professor of life sciences at the University of Bradford, said, “White blood cells are part of the body’s natural defense system. We know that they are under stress when they are fighting cancer or other diseases, so I wondered whether anything measurable could be seen if we put them under further stress with UVA light. We found that people with cancer have DNA which is more easily damaged by ultraviolet light than other people, so the test shows the sensitivity to damage of all the DNA—the genome—in a cell.”
“These are early results completed on three different types of cancer, and we accept that more research needs to be done; but these results so far are remarkable,” said Dr. Anderson. "Whilst the numbers of people we tested are, in epidemiological terms, quite small, in molecular epidemiological terms, the results are powerful. We have identified significant differences between the healthy volunteers, suspected cancer patients, and confirmed cancer patients of mixed ages at a statistically significant level. We believe that this confirms the test’s potential as a diagnostic tool.”
The study was published in the July 25, 2014, online edition of FASEB Journal.
Related Links:
University of Bradford
Investigators at the University of Bradford (United Kingdom) recently described the Lymphocyte Genome Sensitivity (LGS) test that they had developed. This test, which is based on "comet assay" technology, evaluates the damage caused to white blood cell DNA by exposure to different intensities of ultraviolet light (UVA).
The comet assay (single-cell gel electrophoresis) is a simple method for measuring DNA strand breaks in eukaryotic cells. Cells embedded in agarose on a microscope slide are dissolved with detergent and a high salt concentration to form nucleoids containing supercoiled loops of DNA linked to the nuclear matrix. Electrophoresis under alkaline conditions results in structures resembling comets, observed by fluorescence microscopy, with the intensity of the comet tail relative to the head reflecting the number of DNA breaks. Determine of the extent of DNA damage is obtained from visual analysis after DNA staining and calculation of fluorescence, which can be performed by manual scoring or automatically by imaging software.
For their study, the investigators looked at lymphocyte responses from 208 individuals: 20 with melanoma, 34 with colon cancer, four with lung cancer, 18 with suspected melanoma, 28 with polyposis, 10 with COPD (chronic obstructive pulmonary disease), and 94 healthy volunteers. Random and anonymous white blood cell samples were exposed to UVA light through five different depths of agar and then analyzed by the comet assay.
Results revealed that damage to DNA in white blood cells from cancer patients reached a stable plateau after treatment with different UVA intensities. In contrast the response of white blood cells from healthy individuals returned to control values.
Dr. Diana Anderson, professor of life sciences at the University of Bradford, said, “White blood cells are part of the body’s natural defense system. We know that they are under stress when they are fighting cancer or other diseases, so I wondered whether anything measurable could be seen if we put them under further stress with UVA light. We found that people with cancer have DNA which is more easily damaged by ultraviolet light than other people, so the test shows the sensitivity to damage of all the DNA—the genome—in a cell.”
“These are early results completed on three different types of cancer, and we accept that more research needs to be done; but these results so far are remarkable,” said Dr. Anderson. "Whilst the numbers of people we tested are, in epidemiological terms, quite small, in molecular epidemiological terms, the results are powerful. We have identified significant differences between the healthy volunteers, suspected cancer patients, and confirmed cancer patients of mixed ages at a statistically significant level. We believe that this confirms the test’s potential as a diagnostic tool.”
The study was published in the July 25, 2014, online edition of FASEB Journal.
Related Links:
University of Bradford
Latest Pathology News
- Tunable Cell-Sorting Device Holds Potential for Multiple Biomedical Applications
- AI Tool Outperforms Doctors in Spotting Blood Cell Abnormalities
- AI Tool Rapidly Analyzes Complex Cancer Images for Personalized Treatment
- Diagnostic Technology Performs Rapid Biofluid Analysis Using Single Droplet
- Novel Technology Tracks Hidden Cancer Cells Faster
- AI Tool Improves Breast Cancer Detection
- AI Tool Predicts Treatment Success in Rectal Cancer Patients
- Blood Test and Sputum Analysis Predict Acute COPD Exacerbation
- AI Tool to Transform Skin Cancer Detection with Near-Perfect Accuracy
- Unique Immune Signatures Distinguish Rare Autoimmune Condition from Multiple Sclerosis
- Simple Optical Microscopy Method Reveals Hidden Structures in Remarkable Detail
- Hydrogel-Based Technology Isolates Extracellular Vesicles for Early Disease Diagnosis
- AI Tool Improves Accuracy of Skin Cancer Detection
- Highly Sensitive Imaging Technique Detects Myelin Damage
- 3D Genome Mapping Tool to Improve Diagnosis and Treatment of Genetic Diseases
- New Molecular Analysis Tool to Improve Disease Diagnosis
Channels
Clinical Chemistry
view channel
Chemical Imaging Probe Could Track and Treat Prostate Cancer
Prostate cancer remains a leading cause of illness and death among men, with many patients eventually developing resistance to standard hormone-blocking therapies. These drugs often lose effectiveness... Read more
Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
Creatinine has long been the standard for measuring kidney filtration, while cystatin C — a protein produced by all human cells — has been recommended as a complementary marker because it is influenced... Read moreMolecular Diagnostics
view channel
Simple Urine Test to Revolutionize Bladder Cancer Diagnosis and Treatment
Bladder cancer is one of the most common and deadly urological cancers and is marked by a high rate of recurrence. Diagnosis and follow-up still rely heavily on invasive cystoscopy or urine cytology, which... Read more
Blood Test to Enable Earlier and Simpler Detection of Liver Fibrosis
Persistent liver damage caused by alcohol misuse or viral infections can trigger liver fibrosis, a condition in which healthy tissue is gradually replaced by collagen fibers. Even after successful treatment... Read moreHematology
view channel
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
New Test Distinguishes Vaccine-Induced False Positives from Active HIV Infection
Since HIV was identified in 1983, more than 91 million people have contracted the virus, and over 44 million have died from related causes. Today, nearly 40 million individuals worldwide live with HIV-1,... Read more
Gene Signature Test Predicts Response to Key Breast Cancer Treatment
DK4/6 inhibitors paired with hormone therapy have become a cornerstone treatment for advanced HR+/HER2– breast cancer, slowing tumor growth by blocking key proteins that drive cell division.... Read more
Chip Captures Cancer Cells from Blood to Help Select Right Breast Cancer Treatment
Ductal carcinoma in situ (DCIS) accounts for about a quarter of all breast cancer cases and generally carries a good prognosis. This non-invasive form of the disease may or may not become life-threatening.... Read moreMicrobiology
view channel
Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
Sepsis kills 11 million people worldwide every year and generates massive healthcare costs. In the USA and Europe alone, sepsis accounts for USD 100 billion in annual hospitalization expenses.... Read moreRapid POC Tuberculosis Test Provides Results Within 15 Minutes
Tuberculosis remains one of the world’s deadliest infectious diseases, and reducing new cases depends on identifying individuals with latent infection before it progresses. Current diagnostic tools often... Read more
Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
Bloodstream infections in sepsis progress quickly and demand rapid, precise diagnosis. Current blood-culture methods often take one to five days to identify the pathogen, leaving clinicians to treat blindly... Read moreTechnology
view channel
Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Identifying which genetic variants actually cause disease remains one of the biggest challenges in genomic medicine. Each person carries tens of thousands of DNA changes, yet only a few meaningfully alter... Read more
AI Saliva Sensor Enables Early Detection of Head and Neck Cancer
Early detection of head and neck cancer remains difficult because the disease produces few or no symptoms in its earliest stages, and lesions often lie deep within the head or neck, where biopsy or endoscopy... Read moreIndustry
view channel
Abbott Acquires Cancer-Screening Company Exact Sciences
Abbott (Abbott Park, IL, USA) has entered into a definitive agreement to acquire Exact Sciences (Madison, WI, USA), enabling it to enter and lead in fast-growing cancer diagnostics segments.... Read more








